Cargando…
Risk of hypertension in cancer patients treated with abiraterone: a meta-analysis
BACKGROUND: Hypertension is one of the major side effects associated with abiraterone in the treatment of advanced prostate cancer. The specific contribution of abiraterone to hypertension has not been defined. We performed a systematic review and meta-analysis of randomized clinical trials to deter...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6545007/ https://www.ncbi.nlm.nih.gov/pubmed/31168403 http://dx.doi.org/10.1186/s40885-019-0116-x |
_version_ | 1783423333471092736 |
---|---|
author | Zhu, Xiaolei Wu, Shenhong |
author_facet | Zhu, Xiaolei Wu, Shenhong |
author_sort | Zhu, Xiaolei |
collection | PubMed |
description | BACKGROUND: Hypertension is one of the major side effects associated with abiraterone in the treatment of advanced prostate cancer. The specific contribution of abiraterone to hypertension has not been defined. We performed a systematic review and meta-analysis of randomized clinical trials to determine its overall risk. METHODS: Databases including Pubmed (up to July 2018) and Google scholar (up to July 2018) were searched to identify relevant studies. Eligible studies were prospective randomized clinical trials with prostate cancer treated with abiraterone and prednisone. The incidence and relative risk (RR) of hypertension was calculated using random-effects or fixed-effects model depending on the heterogeneity of included studies. RESULTS: A total of five studies including 5445 patients were selected for analysis. Among patients receiving abiraterone, the overall incidences of all grade and high grade (grade 3 and 4) were 21.9% (95% CI: 13.6–33.2%) and 10.2% % (95% CI: 6.9–11.6%). Abiraterone was associated with a significantly increased risk of hypertension of all grade with a relative risk of 1.80 (95% CI: 1.47–2.19%, p < 0.001) and high grade with a relative risk of 2.11 (95%CI: 1.66–2.68%, p < 0.001) in comparison with controls. The risk of hypertension may be affected by concurrent use of prednisone with 5 mg daily is associated with higher incidence than that of prednisone 5 mg twice daily (32.4% vs 16.5%). CONCLUSION: There is a significant increase of developing hypertension in prostate cancer patients treated with abiraterone. Appropriate monitoring and management is strongly recommended to reduce the risk of cardiovascular events and treatment interruptions. |
format | Online Article Text |
id | pubmed-6545007 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-65450072019-06-05 Risk of hypertension in cancer patients treated with abiraterone: a meta-analysis Zhu, Xiaolei Wu, Shenhong Clin Hypertens Research BACKGROUND: Hypertension is one of the major side effects associated with abiraterone in the treatment of advanced prostate cancer. The specific contribution of abiraterone to hypertension has not been defined. We performed a systematic review and meta-analysis of randomized clinical trials to determine its overall risk. METHODS: Databases including Pubmed (up to July 2018) and Google scholar (up to July 2018) were searched to identify relevant studies. Eligible studies were prospective randomized clinical trials with prostate cancer treated with abiraterone and prednisone. The incidence and relative risk (RR) of hypertension was calculated using random-effects or fixed-effects model depending on the heterogeneity of included studies. RESULTS: A total of five studies including 5445 patients were selected for analysis. Among patients receiving abiraterone, the overall incidences of all grade and high grade (grade 3 and 4) were 21.9% (95% CI: 13.6–33.2%) and 10.2% % (95% CI: 6.9–11.6%). Abiraterone was associated with a significantly increased risk of hypertension of all grade with a relative risk of 1.80 (95% CI: 1.47–2.19%, p < 0.001) and high grade with a relative risk of 2.11 (95%CI: 1.66–2.68%, p < 0.001) in comparison with controls. The risk of hypertension may be affected by concurrent use of prednisone with 5 mg daily is associated with higher incidence than that of prednisone 5 mg twice daily (32.4% vs 16.5%). CONCLUSION: There is a significant increase of developing hypertension in prostate cancer patients treated with abiraterone. Appropriate monitoring and management is strongly recommended to reduce the risk of cardiovascular events and treatment interruptions. BioMed Central 2019-06-01 /pmc/articles/PMC6545007/ /pubmed/31168403 http://dx.doi.org/10.1186/s40885-019-0116-x Text en © The Author(s). 2019 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Zhu, Xiaolei Wu, Shenhong Risk of hypertension in cancer patients treated with abiraterone: a meta-analysis |
title | Risk of hypertension in cancer patients treated with abiraterone: a meta-analysis |
title_full | Risk of hypertension in cancer patients treated with abiraterone: a meta-analysis |
title_fullStr | Risk of hypertension in cancer patients treated with abiraterone: a meta-analysis |
title_full_unstemmed | Risk of hypertension in cancer patients treated with abiraterone: a meta-analysis |
title_short | Risk of hypertension in cancer patients treated with abiraterone: a meta-analysis |
title_sort | risk of hypertension in cancer patients treated with abiraterone: a meta-analysis |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6545007/ https://www.ncbi.nlm.nih.gov/pubmed/31168403 http://dx.doi.org/10.1186/s40885-019-0116-x |
work_keys_str_mv | AT zhuxiaolei riskofhypertensionincancerpatientstreatedwithabirateroneametaanalysis AT wushenhong riskofhypertensionincancerpatientstreatedwithabirateroneametaanalysis |